Literature DB >> 23159881

Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis.

Daniel R Getts1, Aaron J Martin, Derrick P McCarthy, Rachael L Terry, Zoe N Hunter, Woon Teck Yap, Meghann Teague Getts, Michael Pleiss, Xunrong Luo, Nicholas J C King, Lonnie D Shea, Stephen D Miller.   

Abstract

Aberrant T-cell activation underlies many autoimmune disorders, yet most attempts to induce T-cell tolerance have failed. Building on previous strategies for tolerance induction that exploited natural mechanisms for clearing apoptotic debris, we show that antigen-decorated microparticles (500-nm diameter) induce long-term T-cell tolerance in mice with relapsing experimental autoimmune encephalomyelitis. Specifically, intravenous infusion of either polystyrene or biodegradable poly(lactide-co-glycolide) microparticles bearing encephalitogenic peptides prevents the onset and modifies the course of the disease. These beneficial effects require microparticle uptake by marginal zone macrophages expressing the scavenger receptor MARCO and are mediated in part by the activity of regulatory T cells, abortive T-cell activation and T-cell anergy. Together these data highlight the potential for using microparticles to target natural apoptotic clearance pathways to inactivate pathogenic T cells and halt the disease process in autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23159881      PMCID: PMC3589822          DOI: 10.1038/nbt.2434

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  49 in total

1.  Scavenger receptors: role in innate immunity and microbial pathogenesis.

Authors:  Thomas Areschoug; Siamon Gordon
Journal:  Cell Microbiol       Date:  2009-04-22       Impact factor: 3.715

2.  Tolerance induced by apoptotic antigen-coupled leukocytes is induced by PD-L1+ and IL-10-producing splenic macrophages and maintained by T regulatory cells.

Authors:  Daniel R Getts; Danielle M Turley; Cassandra E Smith; Christopher T Harp; Derrick McCarthy; Emma M Feeney; Meghann Teague Getts; Aaron J Martin; Xunrong Luo; Rachael L Terry; Nicholas J C King; Stephen D Miller
Journal:  J Immunol       Date:  2011-08-05       Impact factor: 5.422

3.  MARCO regulates early inflammatory responses against influenza: a useful macrophage function with adverse outcome.

Authors:  Sanjukta Ghosh; David Gregory; Alexia Smith; Lester Kobzik
Journal:  Am J Respir Cell Mol Biol       Date:  2011-05-11       Impact factor: 6.914

4.  Antigen-fixed leukocytes tolerize Th2 responses in mouse models of allergy.

Authors:  Charles B Smarr; Chia-Lin Hsu; Adam J Byrne; Stephen D Miller; Paul J Bryce
Journal:  J Immunol       Date:  2011-10-05       Impact factor: 5.422

Review 5.  Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action.

Authors:  Patrice H Lalive; Oliver Neuhaus; Mahdia Benkhoucha; Danielle Burger; Reinhard Hohlfeld; Scott S Zamvil; Martin S Weber
Journal:  CNS Drugs       Date:  2011-05       Impact factor: 5.749

6.  Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.

Authors:  Kevan C Herold; Stephen Gitelman; Carla Greenbaum; Jennifer Puck; William Hagopian; Peter Gottlieb; Peter Sayre; Peter Bianchine; Emelita Wong; Vicki Seyfert-Margolis; Kasia Bourcier; Jeffrey A Bluestone
Journal:  Clin Immunol       Date:  2009-05-14       Impact factor: 3.969

7.  PD-1 ligands expressed on myeloid-derived APC in the CNS regulate T-cell responses in EAE.

Authors:  Bettina Schreiner; Samantha L Bailey; Tahiro Shin; Lieping Chen; Stephen D Miller
Journal:  Eur J Immunol       Date:  2008-10       Impact factor: 5.532

8.  Differential binding of inorganic particles to MARCO.

Authors:  Sheetal A Thakur; Raymond Hamilton; Timo Pikkarainen; Andrij Holian
Journal:  Toxicol Sci       Date:  2008-10-04       Impact factor: 4.849

9.  A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS.

Authors:  M S Freedman; A Bar-Or; J Oger; A Traboulsee; D Patry; C Young; T Olsson; D Li; H-P Hartung; M Krantz; L Ferenczi; T Verco
Journal:  Neurology       Date:  2011-10-05       Impact factor: 9.910

10.  Anti-class a scavenger receptor autoantibodies from systemic lupus erythematosus patients impair phagocytic clearance of apoptotic cells by macrophages in vitro.

Authors:  Xiao-wei Chen; Yan Shen; Chuan-yin Sun; Feng-xia Wu; Yi Chen; Cheng-de Yang
Journal:  Arthritis Res Ther       Date:  2011-01-31       Impact factor: 5.156

View more
  175 in total

1.  An antigen-specific semi-therapeutic treatment with local delivery of tolerogenic factors through a dual-sized microparticle system blocks experimental autoimmune encephalomyelitis.

Authors:  Jonathan J Cho; Joshua M Stewart; Theodore T Drashansky; Maigan A Brusko; Ashley N Zuniga; Kyle J Lorentsen; Benjamin G Keselowsky; Dorina Avram
Journal:  Biomaterials       Date:  2017-07-24       Impact factor: 12.479

2.  Injectable, Pore-Forming Hydrogels for In Vivo Enrichment of Immature Dendritic Cells.

Authors:  Catia S Verbeke; David J Mooney
Journal:  Adv Healthc Mater       Date:  2015-10-16       Impact factor: 9.933

Review 3.  Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches.

Authors:  Robert Pollmann; Thomas Schmidt; Rüdiger Eming; Michael Hertl
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

4.  Designing inorganic nanomaterials for vaccines and immunotherapies.

Authors:  Krystina L Hess; Igor L Medintz; Christopher M Jewell
Journal:  Nano Today       Date:  2019-05-29       Impact factor: 20.722

5.  Therapeutic inflammatory monocyte modulation using immune-modifying microparticles.

Authors:  Daniel R Getts; Rachael L Terry; Meghann Teague Getts; Celine Deffrasnes; Marcus Müller; Caryn van Vreden; Thomas M Ashhurst; Belal Chami; Derrick McCarthy; Huiling Wu; Jin Ma; Aaron Martin; Lonnie D Shae; Paul Witting; Geoffrey S Kansas; Joachim Kühn; Wali Hafezi; Iain L Campbell; David Reilly; Jana Say; Louise Brown; Melanie Y White; Stuart J Cordwell; Steven J Chadban; Edward B Thorp; Shisan Bao; Stephen D Miller; Nicholas J C King
Journal:  Sci Transl Med       Date:  2014-01-15       Impact factor: 17.956

Review 6.  Antigen-specific tolerance in immunotherapy of Th2-associated allergic diseases.

Authors:  Charles B Smarr; Paul J Bryce; Stephen D Miller
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

7.  Design of Polyelectrolyte Multilayers to Promote Immunological Tolerance.

Authors:  Lisa H Tostanoski; Yu-Chieh Chiu; James I Andorko; Ming Guo; Xiangbin Zeng; Peipei Zhang; Walter Royal; Christopher M Jewell
Journal:  ACS Nano       Date:  2016-09-07       Impact factor: 15.881

Review 8.  Regulatory T Cells: Central Concepts from Ontogeny to Therapy.

Authors:  Bernard Khor
Journal:  Transfus Med Rev       Date:  2016-07-26

Review 9.  Trials in type 1 diabetes: Antigen-specific therapies.

Authors:  Ken T Coppieters; Leonard C Harrison; Matthias G von Herrath
Journal:  Clin Immunol       Date:  2013-02-15       Impact factor: 3.969

Review 10.  Overcoming challenges in treating autoimmuntity: Development of tolerogenic immune-modifying nanoparticles.

Authors:  Ryan M Pearson; Joseph R Podojil; Lonnie D Shea; Nicholas J C King; Stephen D Miller; Daniel R Getts
Journal:  Nanomedicine       Date:  2018-10-21       Impact factor: 5.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.